Colorectal Cancer

Amit Mahipal, MBBS, senior associate consultant, Division of Medical Oncology, Department of Oncology, associate professor of oncology, Mayo Clinic, discusses emerging molecular markers in patients with metastatic colorectal cancer (mCRC).

Michael J. Overman, MD, professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses tailoring approaches to molecular subsets of patients with metastatic colorectal cancer.

Jonathan Mizrahi, MD, a hematology/oncology fellow at The University of Texas MD Anderson Cancer Center, discusses the importance of personalized care in patients with metastatic colorectal cancer.

Kristen Ciombor, MD, MSCI, assistant professor of medicine, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, discusses the role of liquid biopsies in colorectal cancer.

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses unmet needs with immunotherapy in metastatic colorectal cancer.

Michael J. Overman, MD, discusses an immunotherapy combination regimen in metastatic colorectal cancer and highlights existing challenges that still need to be addressed in future research.

Marwan Fakih, MD, professor, Department of Medical Oncology and Therapeutics Research, associate director for Clinical Investigations, Comprehensive Cancer Center, medical director, Judy and Bernard Briskin Center for Clinical Research, co-director, Gastrointestinal Cancer Program, and section head, Gastrointestinal Medical Oncology, City of Hope, discusses the use of immunotherapy in patients with microsatellite stable (MSS) colon cancer.

Michael S. Lee, MD, assistant professor of medicine, Department of Molecular Therapeutics, UNC Lineberger Comprehensive Cancer Center, discusses the treatment of patients with newly diagnosed metastatic colorectal cancer.

Cathy Eng, MD, professor of gastrointestinal and medical oncology, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the BEACON CRC study in patients with BRAF-mutated colorectal cancer.

Amit Mahipal, MBBS, senior associate consultant, Division of Medical Oncology, Department of Oncology, associate professor of oncology, Mayo Clinic, discusses maintenance therapy in colorectal cancer (CRC).

Jonathan Mizrahi, MD, discusses recent pivotal data in colorectal cancer and its impact on personalized care in the treatment paradigm.

Marwan Fakih, MD, professor, Department of Medical Oncology and Therapeutics Research, associate director for Clinical Investigations, Comprehensive Cancer Center, medical director, Judy and Bernard Briskin Center for Clinical Research, co-director, Gastrointestinal Cancer Program, and section head, Gastrointestinal Medical Oncology, City of Hope, discusses the use of regional therapy in the treatment of patients with colorectal cancer (CRC).

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown-Lombardi Comprehensive Cancer Center, discusses HER2 amplification in colorectal cancer (CRC).

Michael S. Lee, MD, assistant professor of medicine, Department of Molecular Therapeutics, UNC Lineberger Comprehensive Cancer Center, discusses tailoring treatment to tumor sidedness in patients with metastatic colorectal cancer.

Mohamed E. Salem, MD, a medical oncologist at Levine Cancer Institute, Atrium Health, discusses the results of the MyPathway trial in metastatic colorectal cancer (mCRC).